/

/

atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical...

Thu, Jan 4

Atai Life Sciences Invests $50 Million into Beckley Psytech. The investment gives atai a 35.5% ownership share and exposure to Beckley's advanced trials. https://t.co/l9cMeUl181

161848

Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of...

Discover